Status:

TERMINATED

Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Conditions:

Chronic Hepatitis C

Insulin Resistance

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to test whether the correction of insulin resistance with pioglitazone, will improve the response to antiviral treatment.

Detailed Description

In patients infected with genotypes 1, 4, 5 and 6, the response rate to antiviral therapy remains suboptimal (less than one in two patients have a sustained virological response), which justifies the ...

Eligibility Criteria

Inclusion

  • 18 years old or older
  • Chronic HCV infection documented by PCR with genotype HCV-1, 4, 5 or 6
  • Naive Patient(never treated with antivirals for HCV)
  • HOMA score higher than 2.5
  • Patient for which the investigator decided to start antiviral treatment for chronic hepatitis C

Exclusion

  • Cardiovascular disease: heart failure stage NYHA II, III or IV, unstable angina, myocardial infarction in the previous year, cardiac surgery or stroke
  • Alcohol consumption exceeding 40 g / day
  • Decompensated liver disease: Child-Pugh B 8 or higher, or one of the following : bilirubin over 35 mol / L, TP below 50%, ascites, encephalopathy
  • Hepatocellular carcinoma or any other neoplasm (except if in remission for \> 5 years)
  • Other documented chronic liver disease
  • Insulin treated diabetes
  • HBV or HIV co-infection infection confirmed
  • Thrombocytopenia below 50 000/mm ³; neutropenia below 750/mm ³ or hemoglobin below 11 g / dL
  • Drug-induced steatosis(tamoxifen, glucocorticosteroids, amiodarone, tetracyclines).
  • Bone marrow or solid organ transplantation
  • Pregnancy or breastfeeding, or desire for pregnancy during the study period.
  • Patients under legal protection or unable to express their consent

Key Trial Info

Start Date :

December 3 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 6 2012

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00927290

Start Date

December 3 2009

End Date

July 6 2012

Last Update

January 24 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital Pitié Salpêtrière, Service d'hépatogastroentérologie

Paris, France, 75013